Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold
- 1 May 2021
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 217, 113377
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cellsOncotarget, 2017
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib StudyJournal of Clinical Oncology, 2017
- Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1Journal of Medicinal Chemistry, 2017
- Durvalumab: First Global ApprovalDrugs, 2017
- Atezolizumab: A PD-L1–Blocking Antibody for Bladder CancerClinical Cancer Research, 2017
- Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)Oncotarget, 2016
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1Structure, 2015
- PembrolizumabJournal for ImmunoTherapy of Cancer, 2015
- Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises ExpectationsJournal of Clinical Oncology, 2014
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012